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At a glance commentary: 
Scientific knowledge on the subject 
A major challenge in RSV research is to understand why infection recurs throughout life, despite 
a high degree of viral genetic stability. Passive antibody thereapy protects against hospitalization 
of high-risk infants, but new and better correlates of protection are needed that more accurately 
predict candidate vaccine efficacy. 
What this study adds to the field 
We find that virus-specific nasal IgA correlates with protection against experimental RSV 
challenge in adult volunteers, and replaces serum neutralizing antibody as the best predictor of 
protection. However, virus-specific IgA memory B cell responses are remarkably absent after 
RSV infection, possibly explaining susceptibility to re-infection. Ideally, RSV vaccines 
should  induce durable mucosal antiviral IgA and memory B cells thereby overcoming the 
defective responses seen after infection with live virus. 
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org 
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Abstract: 
Rationale: Despite relative antigenic stability, respiratory syncytial virus (RSV) re-infects 
throughout life. After >40 years of research, no effective human vaccine exists and correlates of 
protection remain poorly defined. Most current vaccine candidates seek to induce high levels of 
RSV-specific serum neutralizing antibodies, which are associated with reduced RSV-related 
hospitalization rates in observational studies but may not actually prevent infection. 
Objectives: Characterize correlates of protection from infection and the generation of RSV-
specific humoral memory to promote effective vaccine development. 
Methods: We inoculated 61 healthy adults with live RSV and studied protection from infection 
by serum and mucosal antibody. We analyzed RSV-specific peripheral blood plasmablast and 
memory B cell frequencies and antibody longevity. 
Measurements and Main Results: Despite moderately high levels of pre-existing serum 
antibody, 34 (56%) became infected, of whom 23 (68%) developed symptomatic colds. Prior 
RSV-specific nasal IgA correlated significantly more strongly with protection from PCR-
confirmed infection than serum neutralizing antibody. Increases in virus-specific antibody titers 
were variable and transient in infected subjects, but correlated with plasmablasts that peaked 
around day 10. During convalescence, only IgG (and no IgA) RSV-specific memory B cells were 
detectable in peripheral blood. This contrasted with natural influenza infection, where virus-
specific IgA memory B cells were readily recovered. 
Conclusions: This observed specific defect in IgA memory may partly explain RSV’s ability to 
cause recurrent symptomatic infections. If so, vaccines able to induce durable RSV-specific IgA 
responses may be more protective than those generating systemic antibody alone. 
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Introduction 
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization worldwide, 
infecting around 34 million children each year (1). It is also a major under-appreciated 
contributor to morbidity and mortality in elderly and immunosuppressed adults (2). While RSV 
infection is essentially confined to the respiratory epithelium, extensive lung inflammation 
frequently causes life-threatening disease in these at-risk populations (3, 4). It remains one of the 
few common severe infections for which there is no specific intervention and an effective 
vaccine represents a major unmet need. 
 
Natural infections with most viruses including influenza and rhinoviruses induce long-lasting 
protective immunity, with recurrent infections then occurring because of antigenic variation. In 
contrast, re-infection with identical strains of RSV can occur at as little as 2 month intervals even 
with a healthy mature immune system (5). Although re-infection with human metapneumovirus 
and parainfluenza viruses have been observed, only RSV has been categorically shown to induce 
recurrent symptomatic disease in the absence of antigenic change (6, 7). The mechanisms 
underlying this phenomenon remain unclear and the lack of durable immunity after natural 
infection has made it difficult to define precise correlates of protection. With over 51 RSV 
vaccine candidates currently in development (8), the ability to predict efficacy via immune 
correlates is urgently required. Although the humanized monoclonal IgG palivizumab can reduce 
infant hospitalizations with RSV by at least 50% (9), the association between serum antibody 
levels and protection is imprecise (10, 11). Therefore, the value of serum antibody induction as 
the primary readout of potential vaccine candidates and in vaccine licensure may be limited.  
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While animal models of RSV infection provide mechanistic insights, they do not recapitulate all 
aspects of human disease and remain imprecise guides to the clinical efficacy of vaccines (12). 
Investigation of hospitalized children and high-risk adults allows natural disease to be observed, 
but cannot correlate prior immune status with susceptibility to infection. In addition, lack of 
uniformity in virus inoculum, co-morbidities, medical interventions and atypical disease 
presentations limit the conclusions that can be reached from these observational studies. 
Experimental infection of volunteers therefore offers an important complementary approach, 
allowing intensive sampling and the opportunity to perform detailed investigations of pre-
existing and pre-symptomatic responses (13, 14). 
 
To investigate the mechanisms underlying recurrent RSV infection, we analyzed antibody-
mediated protection and B cell responses before and after experimental human challenge. We 
found that serum antibody was loosely correlated with protection, but that there was a tight 
relationship between pre-existing RSV-specific nasal antibody and resistance to infection. These 
data allowed us to derive a model that accurately predicts infection risk. In addition, we 
demonstrate a novel RSV-specific defect in IgA memory that may explain the susceptibility to 
re-infection with RSV and discuss its implications for RSV vaccine development. Some of the 
results of this study have been previously reported in the form of abstracts (15–19). 
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Materials and Methods 
Study design 
Healthy non-smoking adults aged 18-55 were eligible for inclusion. All were screened to exclude 
underlying immunodeficiencies including IgA deficiency by serum immunoglobulin class levels. 
Subjects were inoculated with with 104 plaque-forming units (PFU) of RSV A Memphis 37 
(RSV M37) by intranasal drops (as defined in previous dose-ranging studies) and quarantined 
from 1 day prior to inoculation to the 10th day after (13). Nasal washes and blood were taken 
immediately before inoculation and regularly for the next 10 days (Supplementary Fig. E1A). 
Infection was defined as RSV detectable by PCR in nasal lavage on ≥2 days between day +2 and 
day +10 to avoid false positives from detection of the viral inoculum and to align case definitions 
with previous challenge studies using RSV M37 (13). Subjects completed a diary of upper 
respiratory tract symptoms (see Online Data Supplement) from day -1 to day +14. All subjects 
returned for further nasal and blood sampling on day +14, +28 and optionally 6-12 months after 
inoculation (nominally day +180). All subjects provided written informed consent and the study 
was approved by the UK National Research Ethics Service (study numbers 10/H0711/94 and 
11/LO/1826). 
Antibody assays 
Serum neutralizing antibody titer was determined by plaque reduction neutralization titer 
(PRNT) in HEp-2 cells and expressed as mid-point titers (EC50). Sera from 4 hospitalized RSV 
PCR negative infants hospitalized were included as negative controls and 3 RSV immune 
reference sera (Wyeth 06937, 06938, 06939) as positive controls (20). Nasal wash IgA endpoint 
binding titer to RSV lysate and F protein was determined by enzyme-linked immunosorbent 
assay (ELISA) as the highest titer exhibiting an optical density of >2x the background. End-point 
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titers were used as mid-point titers could not be calculated in view of the dilute nature of nasal 
lavage. Observed endpoint titers were corrected for dilution using the ratio of serum to nasal 
lavage urea before analysis as described (21). 
Detection of antibody secreting cells by B cell ELISpot 
Antibody secreting cells (ASCs) were detected using enzyme-linked immunospot (ELISpot) as 
previously described (22), using whole RSV M37 lysate from Hep-2 cells and recombinant F 
protein based on the RSV A2 strain (see Online Data Supplement for detailed methods). For 
memory B cells, additional plates were coated with 10µg/mL measles antigen (Meridian 
Lifesciences), and 5µg/mL HEp-2 antigen, 2.5µg/mL keyhole limpet hemocyanin (KLH, Sigma), 
and media as negative controls. Total ASCs were expressed as spot-forming cells / 106 PBMC 
and antigen-specific ASCs as % of total Ig-secreting cells. 
Polyclonal activation of memory B cells 
PBMCs were cultured in vitro according to the method of Crotty et al. (23). The alternative 
polyclonal activation mix described by Tengvall et al. was used in a subset of samples (24). 
ASCs were detected by B cell ELISpot as above. Subjects exhibiting a total Ig+ cell responses 
the below the 10th centile in either the day 0 or day 28 sample for either IgG or IgA were 
excluded (n = 9) as inadequate responders to stimulation.  
Statistical analysis 
All data analyses and graphs were produced using the software R (25, 26). Results are expressed 
as median and interquartile range. Non-parametric data was compared using Mann-Whitney-
Wilcoxon tests with Holm’s correction for multiple comparisons. Binary response variables were 
related to continuous explanatory variables using logistic regression. Odds ratios (OR) and 95% 
Defective respiratory syncytial virus IgA memory  
 
 7 
confidence intervals (CI) of the OR for the explanatory variables were calculated (see Online 
Data Supplement). For estimation of serum neutralizing antibody titers, weighted (1/y) four-
parameter logistic models were fitted to the plaque counts and the 50% neutralizing titer (EC50) 
was derived from the midpoint of the curve using package ‘drc’ (27).  
 
Results  
Nasal antibody correlates strongly with protection from infection by RSV 
Sixty-one healthy non-smoking adult volunteers were enrolled (age 18-50, median 22 years; 
Table 1) without pre-selection according to anti-RSV antibody levels. All were inoculated with 
RSV M37 via nasal drops and admitted to a residential quarantine facility for 10 days. Thirty-
four (56%) subjects became infected as defined by PCR positivity on ≥2 consecutive days 
between days 2-10 post-inoculation (Supplementary Fig E1B). Five individuals deemed 
“uninfected” had a low level of detectable viral shedding on day 1 post-inoculation with no virus 
detected at any point thereafter, which likely indicated the remains of the virus inoculum and not 
evidence of productive infection. Two “uninfected” subjects had RSV detected with a high Ct 
value on a single day during days 2-10. Neither of these had any subsequent change in their 
RSV-specific immune responses. Median (interquartile range, IQR) cumulative symptom scores 
were 26.5 (9.6–41.9) for PCR+ “infected” and 9.0 (0.8–20.3) for PCR- “uninfected” subjects (P 
= 0.004). Daily nasal lavage viral load measurements were made during the quarantine period 
and cumulative viral load for PCR+ subjects was 4.0 (3.1–5.2) log10 copies/mL. No difference in 
the number infected was observed for differing age, sex or ethnicity. 
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Pre-existing PRNTs did not differ significantly between PCR- (median 7.8 log2) and PCR+ 
(median 7.6 log2) subjects (Fig 1A). Similarly, there was no significant difference in anti-RSV or 
anti-F protein IgG (RSV-IgG 7.8 log2 vs. 7.6 log2, F-IgG 7.9 log2 vs. 7.2 log2) or IgA (RSV-IgA 
9.0 log2 vs. 8.0 log2, F-IgA 8.0 log2 vs. 7.5 log2) in serum between PCR- and PCR+ individuals 
(Supplementary Fig. E2A & E2B). By contrast, nasal anti-RSV and anti-F protein IgA titers in 
individuals who remained uninfected were significantly higher (RSV-IgA 10.1 log2 vs. 9.4 log2, 
F-IgA 10.2 log2 vs. 9.6 log2 Fig. 1A). However, serum IgA correlated poorly with nasal IgA (the 
Spearman’s correlation coefficient of 0.25 implying only a weak relationship between responses 
against RSV lysate in these compartments with a borderline P-value of 0.05), suggesting that it is 
IgA in the airway that specifically plays a role in protection against RSV infection and that 
serum IgA may not derive from the same source (Supplementary Fig. E2C). 
 
Serum antibody (PRNT) did not affect the likelihood of infection (odds ratio (OR) = 1.6, 95% 
confidence interval 0.9–2.9, P = 0.1), but virus- and F protein-specific nasal IgA were again 
significantly associated with protection (RSV-IgA: OR = 1.9 (1.2–3.4), P = 0.014; F-IgA: OR = 
1.7 (1.1–2.9), P = 0.016, Fig. 1B). Thus, serum antibody correlates poorly with protection 
whereas a 1 log2 increase in RSV-specific nasal IgA titers renders subjects nearly twice as likely 
to be protected.  
 
Increased RSV-specific antibody levels after infection are poorly maintained 
Following RSV challenge, RSV PCR+ subjects showed a median 3.4–fold increase in PRNT 
(IQR 2.3–4.6). Similar increments were seen in nasal anti-RSV IgA (2.6 fold, IQR 2.0–5.4) and 
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nasal anti-F protein IgA (3.0, 1.4–4.5). By contrast, in the group that was inoculated but 
remained uninfected, no significant rise in the median neutralization titer (1.4, 1.0–2.0), nasal 
anti-RSV IgA (0.9, 0.6–2.5) or nasal anti-F protein IgA (0.8, 0.6–1.6; Fig. 2A) was seen by 
Mann-Whitney test. Although two uninfected individuals displayed a 4-fold rise in PRNT and 8 
showed approximately 2-fold increases in nasal anti-RSV IgA, none were PCR+ on any day. 
Repetition of these assays showed no run-to-run variability, suggesting that these changes 
represented either normal biological variability in serum antibody levels or responses to RSV 
antigen in the inoculum in the absence of infection.  
 
Whilst prior nasal IgA levels correlated closely with protection, only 21% of individuals judged 
as infected reached post-infection nasal anti-RSV IgA titers predicted to give ≥80% protection 
(Supplementary Table E1). Even fewer subjects demonstrated an equivalently protective rise in 
IgA specific to purified RSV F protein (9%), suggesting that a proportion of antibody boosted by 
natural infection might be against strain-specific variable sites on surface glycoproteins. 
Therefore, even the boosted levels of antibody seen shortly after natural infection are unlikely to 
provide complete immunity in most individuals. 
 
Previous studies have suggested that antibodies induced by RSV infection are poorly maintained 
in both adults (28) and children (29). We therefore measured serum and nasal anti-RSV 
antibodies in infected subjects approximately 6-12 months post-inoculation. Even in infected 
subjects showing the strongest antibody responses in serum and/or nasal secretions at one month, 
antibody levels were not maintained at later follow-up. Instead, levels returned in many to almost 
exactly the pre-infection level for that individual (Fig. 2B). 
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Induction of higher plasmablast frequencies correlates with increased antibody levels 
To better understand why RSV-specific antibodies neither reach consistently protective titers nor 
persist beyond 6 months, we studied B cell responses in peripheral blood by flow cytometry. 
RSV-induced plasmablasts (CD3-/CD19+/CD38hi/CD27hi) peaked around 10 days post-
inoculation (Supplementary Fig. E3A). Similarly, using B cell ELISpots, antigen-specific 
antibody-secreting cells (ASCs) against RSV were shown to arise after day +7 and peak around 
day +10 (Fig. 3A). Peak virus-specific ASC frequencies ranged from 5-50% of total ASCs, 
comparable to that after influenza or yellow fever vaccination (Fig. 3B) (30–33). Thus, the virus-
specific acute ASC responses to RSV infection appeared quantitatively intact. 
 
By day +14, RSV-specific ASCs had declined and by day +28 were completely undetectable. 
IgM-producing ASCs were largely absent throughout (as expected of a recall response). 
However, IgG- and IgA-producing RSV-specific ASCs both appeared at similar frequencies, 
consistent with generation at a mucosal site of infection (Fig. 3B). Furthermore, the frequency of 
RSV- and F-specific IgG+ ASCs correlated strongly with fold-change in serum neutralizing 
antibody (Fig. 3C and Supplementary Fig. E3B) and virus-specific IgA+ ASCs correlated 
strongly with the increment in nasal IgA (Fig. 3D and Supplementary Fig. E3B). However, pre-
existing serum neutralizing antibody levels negatively correlated with peak ASC frequencies, 
suggesting that even though antibodies in this compartment did not provide sterilizing immunity, 
they might still have blunted responses against homologous antigens in the challenge agent (Fig. 
3E and Supplementary Fig. E3C). Further, cumulative viral load and symptom scores (by 
trapezoidal area under the curve (AUC)) were not associated with peak ASC frequencies, 
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indicating that once infection was established the frequency of antigen-specific B cells had no 
effect on virus control or disease severity (Supplementary Fig. E4A & E4B). Therefore, the peak 
frequency of ASCs depended on pre-existing antibodies inasmuch as antibody can prevent the 
establishment of infection. Once infection occurred, ASCs proliferated rapidly; this correlated 
with the transient production of anti-RSV IgG and IgA, but otherwise had little impact on disease 
course or outcome. 
 
IgG+ memory B cell frequencies prior to infection do not influence the outcome of viral 
challenge  
Circulating memory B cells (MBCs) rapidly differentiate into ASCs and plasma cells on re-
encounter with cognate antigen and are essential for rapid humoral response to recurrent 
infection. To assess whether pre-infection RSV-specific MBCs correlate with protection we 
analyzed RSV-specific MBC frequencies and compared with those against measles virus, a 
related pathogen to which protection following natural infection or live-attenuated vaccination is 
known to be long-lasting (34). 
 
Identifying ASCs by B cell ELISpot (23), there were no significant differences in IgG+ MBC 
frequencies against whole RSV, F-protein or measles virus prior to RSV challenge or between 
pre-infection MBC frequencies in subsequently infected or uninfected subjects (Fig. 4A). Pre-
infection MBC frequencies neither correlated with later symptom score nor viral load in infected 
subjects (Supplementary Fig. E5A & E5B), nor with PRNT or nasal IgA antibody levels 
(Supplementary Fig. E5C, E5D, & E5E). This confirmed that pre-existing RSV-specific MBCs 
Defective respiratory syncytial virus IgA memory  
 
 12 
per se neither influence infection rates nor contribute to control of disease or viral replication 
once infection is established. 
 
Following infection, subjects demonstrated a median (IQR) increase in IgG+ MBC frequencies of 
0.4 (0.2−0.5) % against whole RSV and 0.1 (0−0.2) % against F protein (Fig. 4A). These equated 
to a median 3.8 (3.1−5.1) –fold increase in RSV-specific MBCs and 1.8 (1.3−4.4) –fold increase 
in F-specific MBCs compared with pre-infection frequencies (Fig. 4B). By contrast, measles-
specific IgG+ MBC frequencies remained unchanged (Fig. 4A & 4B). The fold-change in both 
virus- and F-protein specific IgG+ MBCs correlated with the size of ASC burst specific for the 
homologous antigens, suggesting that these populations were generated by associated 
mechanisms (Fig. 4C). IgG+ MBCs therefore incremented appropriately following RSV infection 
but did not affect the course of acute disease.  
 
RSV infection fails to induce virus-specific IgA memory B cells 
To investigate the mechanisms underlying the decline in virus-specific nasal IgA, we studied 
RSV-specific IgA+ MBCs. In contrast to IgG+ MBCs, RSV- and F-specific IgA-producing 
MBCs (and measles-specific IgA+ MBCs) were undetectable pre-infection (Fig. 5A). Strikingly, 
anti-RSV IgA+ MBCs then demonstrated no detectable increase in frequency even shortly after 
RSV infection; these remained undetectable at convalescence in the same way as measles (Fig. 
5B). 
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IgA+ and IgG+ MBCs differ in their requirements for optimal in vitro activation (24). To ensure 
that the apparent absence of RSV-specific IgA+ MBCs was not simply due to inadequate 
activation, we repeated the in vitro activation of PBMC from 6 selected subjects who had 
previously demonstrated a robust RSV-specific IgG+ MBC response with an alternative protocol 
using CpG, l and IL-15 to enhance IgA+ MBC stimulation (24). However, this did not improve 
the polyclonal stimulation of IgA+ MBCs, which were induced at similar frequencies to the 
original method, while total IgG+ MBCs were less well induced (Supplementary Fig. E6A & 
E6B). Again, RSV-specific IgA+ MBCs were undetectable both at baseline and convalescence 
using either stimulation method (Supplementary Fig. E6C & E6D). 
 
To determine whether poor IgA+ MBC generation was RSV-specific, we compared these 
responses with those after natural influenza A(H1N1)pdm09 infection. Convalescent PBMCs 
were obtained as part of the Mechanisms of Severe Acute Influenza Consortium (MOSAIC) 
study from 8 patients hospitalized with virologically-confirmed pdmH1N1 infection during the 
2009/10 and 2010/11 influenza seasons. All were previously healthy with no known 
immunosuppressive disease. Antigen-specific MBCs were polyclonally stimulated under 
identical conditions and identified by B cell ELISpot. As expected, the virus-specific IgG+ 
MBCs induced following both pdmH1N1 and RSV were found at similar frequencies (Fig. 5C). 
However, PBMCs from patients naturally infected with influenza showed no defect in IgA+ 
MBC response, with significantly higher numbers of virus-specific IgA+ MBCs than in those 
infected with RSV (Fig. 5D). In influenza, virus-specific IgA+ and IgG+ MBC numbers were 
therefore comparable and IgA+ MBCs were generally abundant in those who had recovered from 
infection, contrasting with the paucity of IgA+ MBCs after RSV infection.  
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Discussion  
In this study, we show that mucosal IgA titers are predictive of susceptibility to RSV infection 
(in contrast to serum antibody levels which are not), and identify a previously unrecognized 
defect in IgA memory B cell responses to RSV. The few previous studies of mucosal IgA in 
RSV disease have been restricted in their applicability by study design and other technical 
limitations (35–37). Our investigations now show the power of the experimental human infection 
model, which for the first time has allowed development of a tightly predictive model of RSV 
infection risk in seropositive individuals.  
 
A previous study examining the protective role of RSV-specific antibodies during experimental 
human RSV challenge (38) showed that serum neutralization and IgG titers against F protein 
were both significantly higher in those remaining uninfected, whilst no difference was seen in 
nasal IgA titers. The reasons for the discrepancy between those results and our present findings 
may be methodological: in the earlier study, a different method of nasal lavage was used, 
resulting in a more dilute sample and average 2-3 fold lower nasal IgA titer. The normalization 
according to total protein content may also have led to underestimation of true IgA level. In 
addition, the laboratory-adapted RSV A2 strain used in the previous study induced little 
symptomatic disease in infected subjects and may have had different host-virus dynamics 
compared with RSV M37, a more recent, non-attenuated, clinically derived strain. Finally, the 
previous study included fewer subjects (a total of 28 inoculated individuals), some of whom 
were pre-stratified on the basis of serum antibody levels, which may have affected the analyses. 
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Interestingly, consistently protective levels of anti-RSV IgA were only seen in a small minority 
of individuals, even during early convalescence . Furthermore, while antibodies were temporarily 
boosted by infection, titers waned to pre-infection steady-state levels within 6-12 months. This 
contrasts sharply with known responses to viruses such as influenza or rhinovirus, in which 
strain-specific serum IgG can persist life-long and nasal IgA remain significantly raised for a 
year or more (39, 40). Antibody responses to RSV infection are therefore remarkably transient, 
accounting for the frequency of adult re-infection. This study now sets a new goal for vaccine-
induced immunity: mucosal IgA responses in the respiratory mucosa beyond those induced 
naturally. Indeed, if mucosal IgA could be induced in the major at-risk population of young 
children, there would be advantages not only in reducing the incidence of RSV infection but also 
by limiting the extent of virus transmission, although extrapolation of these data to children 
should be undertaken with caution. 
 
Importantly, we found that short-lived RSV-specific IgG+ and IgA+ B cells were generated 
robustly at comparable frequencies to those observed following other challenges including 
influenza infection or vaccination (30, 32). With acute production of short-lived ASCs 
apparently intact, a vaccine capable of inducing higher frequencies of these cells should also 
induce greater antibody responses and therefore enhanced protection. Previous studies in natural 
RSV infection of adults indicated that this might be further modulated by duration of antigenic 
stimulation, with prolonged viral shedding driving ASC responses (41). However, anti-RSV 
antibody titers were poorly maintained, implying a defect in long-lived plasma cells (LLPCs) 
that arise from the ASC population and which normally migrate to survival niches including 
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bone marrow and respiratory mucosa (42, 43). Future studies to address this contention will 
require direct sampling of these compartments, which may be difficult.  
 
In animal models, IgA-producing B cells are abundant at mucosal sites (44) and appear rapidly in 
mucosal tissues under the influence of mediators such as BAFF (B cell activating factor) and 
APRIL (A proliferation inducing ligand) (45–47). However, to generate high affinity antibodies 
and long-term memory responses, antigen-presenting cells, B cells and T follicular helper (Tfh) 
cells must interact in germinal centers (GCs) (48, 49). T cell help allows not only class-switching 
to IgA but also the promotion of ASC and MBC formation (50, 51). MBCs require many of the 
same differentiation signals as LLPCs and we therefore hypothesized that MBC responses would 
also be sub-optimal. Our analysis of IgG+ MBCs pre- and post-infection found no evident defect, 
but remarkably, we were unable to detect any RSV-specific IgA+ MBCs prior to infection and no 
increment in IgA+ MBC frequency afterwards. Since the acute ASC response was dominated by 
RSV-specific IgA+ ASCs, which are likely to have arisen from pre-existing IgA+ MBCs, the 
finding that RSV-specific IgA+ MBCs were so infrequent both pre- and post- infection was 
highly unexpected. Despite this, moderate levels of serum and nasal IgA against RSV could be 
detected in all volunteers. Thus, while incremental boosting of IgA+ MBCs might be poor, over 
multiple re-infections LLPCs in bone marrow or respiratory tract are likely to have developed 
that are capable of producing RSV-specific IgA long-term but whose population size or 
antibody-producing capabilities are minimally augmented following re-challenge. 
 
RSV is known to express several immunomodulatory proteins and we therefore suggest that this 
defect in IgA memory represents a viral immune evasion strategy. However, some alternative 
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explanations should be considered. It is possible that IgA+ MBCs following respiratory 
infections in general are so infrequent that these assays cannot detect them. Alternatively, IgA+ 
MBCs might be preferentially retained in mucosal sites and therefore not detectable in the 
circulation. However, if either of these were the case, we would also not have expected to find 
influenza-specific IgA+ MBCs in convalescent PBMCs. Furthermore, studies of oral cholera 
vaccination show that vaccine antigen-specific IgA+ MBCs do appear in the circulation of 
vaccinees (52). It could be argued that the more vigorous inflammatory response to influenza is 
responsible for induction of a greater overall humoral response, thus explaining the longer 
persistence of mucosal IgA and higher frequencies of influenza-specific MBCs. However, there 
was no difference in the frequency of IgG+ MBCs between the two infections, suggesting that 
generalized deficiency of inflammatory signaling was unlikely to have been the cause of reduced 
anti-RSV IgA+ MBCs. By contrast, intranasal infection with attenuated influenza strains and 
rhinoviruses are still capable of inducing persistent humoral responses despite causing less 
inflammation than RSV (40, 53). 
 
We therefore propose the hypothesis that RSV infection is unusual in limiting the induction of B 
cell memory responses in the respiratory tract. This would explain why the defect is specifically 
in IgA+ MBCs (which are preferentially generated at mucosal sites) and does not affect IgG+ 
MBCs. Recent studies have suggested that while BAFF is elevated in BAL and bronchial 
brushings from children with RSV bronchiolitis, APRIL is not (54). In addition, defects in RSV 
antigen-presentation and T cell memory generation have been observed in several animal 
models, which may impact on Tfh cell activity (55). Thus, both T cell-independent and 
dependent mechanisms may be influenced by RSV to specifically impair local immunity. If few 
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IgA+ MBCs are induced following infection, this may explain why antibody-mediated immunity 
plateaus despite recurrent virus exposure. Further mechanistic investigation to support this 
interpretation will require invasive respiratory tract sampling of infected individuals, since no 
animal model experiences recurrent symptomatic RSV infections. It also remains to be seen 
whether similar mechanisms exist in human metapneumovirus or other respiratory viruses where 
recurrent infections occur. 
 
The ability to predict infection risk using nasal IgA titers and discovery of a specific defect in 
IgA memory have important implications for RSV vaccine development. Although findings from 
experimental infection of young adults may not be directly applied to infants and elderly 
individuals, they can be extrapolated to women of child-bearing age in whom mucosal 
vaccination may reduce RSV transmission to their children and confer a “cocooning” effect. 
Community cohort studies will support the applicability of these data in high-risk populations, 
but our results suggest that vaccines inducing mucosal RSV-specific IgA are likely to be more 
effective than those stimulating systemic antibodies alone. For vaccines that induce local virus-
specific IgA, we can also now accurately predict their protective efficacy prior to commitment to 
phase II/III clinical trials and for licensing purposes. However, the unique absence of IgA+ 
MBCs following RSV infection will necessitate re-consideration of which types of vaccine to 
pursue. Live-attenuated RSV vaccines, for example, may also be subject to this same defect and 
be incapable of inducing sufficient long-lived IgA to provide solid protection (56). Even novel 
vaccine constructs that might bypass this defect will encounter this limitation, with the paucity of 
pre-existing IgA+ MBCs necessitating multiple-boost regimens. 
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In conclusion, we demonstrate that nasal antibody strongly predicts protection from RSV 
infection in adults. However, antibody levels wane much more rapidly than reported in other 
respiratory viral infections and are almost always below those needed for protection within 
months. Unexpectedly, we found that RSV-specific IgA+ memory B cells were not significantly 
induced by infection, implying that effective RSV vaccines may need to overcome this defect to 
provide durable immunity. 
 
 
Acknowledgments: We thank Gaynor Campbell, Natasha Gunawardana, Laura Medrano 
González and Jonathan Spencer for their technical assistance, and the study volunteers 
for their generosity and tolerance. 
  
Defective respiratory syncytial virus IgA memory  
 
 20 
References 
1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, 
Wright PF, Bruce N. Global burden of acute lower respiratory infections due to respiratory 
syncytial virus in young children: a systematic review and meta-analysis. The Lancet 
2010;375:1545–1555. 
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus 
Infection in Elderly and High-Risk Adults. N Engl J Med 2005;352:1749–1759. 
3. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory Syncytial Virus 
Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and 
without Obvious Cytopathology. J Virol 2002;76:5654–5666. 
4. Gardner PS, McQuillin J, Court SDM. Speculation on Pathogenesis in Death from 
Respiratory Syncytial Virus Infection. Br Med J 1970;1:327–330. 
5. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with 
respiratory syncytial virus. J Infect Dis 1991;163:693–698. 
6. Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Nishimura H, Matsuzaki Y. 
Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy 
adults. J Med Virol 2010;82:2092–2096. 
7. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk 
of infection and reinfection in young children. J Infect Dis 1984;150:851–857. 
6. PATH. 2014. Respiratory syncytial virus: Vaccine development against a major cause of 
childhood respiratory illness. [Online]. [Accessed 16th December 2014]. Available from: 
http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/. 
Defective respiratory syncytial virus IgA memory  
 
 21 
9. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus 
monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in 
high-risk infants. Pediatrics 1998;102:531–537. 
10. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus 
infection in elderly adults. J Infect Dis 1998;177:463–466. 
11. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to 
respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum 
protective threshold levels of serum neutralizing antibodies. Vaccine 2003;21:3479–3482. 
12. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial 
virus disease. Am J Physiol Lung Cell Mol Physiol 2011;301:L148–156. 
13. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, 
Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, 
Dorsett P, Alvarez R, Lambkin-Williams R. Viral load drives disease in humans 
experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 
2010;182:1305–1314. 
14. Pollard AJ, Savulescu J, Oxford J, Hill AV, Levine MM, Lewis DJ, Read RC, Graham DY, 
Sun W, Openshaw P, Gordon SB. Human microbial challenge: the ultimate animal model. 
Lancet Infect Dis 2012;12:903–905. 
15. Chiu C, Habibi MS, Jozwik A, Paras A, Makris S, Openshaw PJM. B cell responses 
following experimental RSV challenge in adult volunteers. Porto, Portugal: 2013.  
16. Habibi MS, Jozwik A, Makris S, Paras A, Openshaw P, Chiu C. Human B cell responses 
following experimental respiratory syncytial virus challenge. Jesus College, Cambridge, UK: 
2013.  
Defective respiratory syncytial virus IgA memory  
 
 22 
17. Habibi MS, Guvenel AK, Jozwik A, Paras A, Chiu C, Openshaw PJM. Immunity to 
Respiratory Syncytial Virus (RSV) infection. Pathog Respir Viruses J5 Keystone, Colorado, 
USA: 2014.  
18. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, Wrammert J, Openshaw PJM, Chiu C. 
Defective IgA B cell memory generation following experimental human respiratory syncytial 
virus infection impairs protective immunity. Stellenbosch, South Africa: 2014.  
19. Medrano González L, Habibi MS, Jozwik A, Openshaw PJM, Chiu, Christopher. Quality of 
antigen-specific B cell responses as a correlate of protection against RSV. Immunology 
2014;143:75. 
20. Yang DP, Zielinska E, Quiroz J, Madore D, Rappaport R. Preparation of a respiratory 
syncytial virus human reference serum for use in the quantitation of neutralization antibody. 
Biol J Int Assoc Biol Stand 2007;35:183–187. 
21. Rennard SI, Basset G, Lecossier D, O’Donnell KM, Pinkston P, Martin PG, Crystal RG. 
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of 
dilution. J Appl Physiol Bethesda Md 1985 1986;60:532–538. 
22. Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Enzyme-linked immunospot assays for 
direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. 
Nat Protoc 2013;8:1073–1087. 
23. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B 
cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004;286:111–122. 
24. Tengvall S, Lundgren A, Quiding-Järbrink M, Svennerholm A-M. BAFF, stimulatory DNA 
and IL-15 stimulates IgA+ memory B cells and provides a novel approach for analysis of 
memory responses to mucosal vaccines. Vaccine 2010;28:5445–5450. 
Defective respiratory syncytial virus IgA memory  
 
 23 
25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 
R Foundation for Statistical Computing; 2013. at <http://www.R-project.org/>. 
26. Sarkar D. Lattice: Multivariate Data Visualization with R. New York: Springer; 2008. at 
<http://lmdvr.r-forge.r-project.org>. 
27. Ritz C, Streibig JC. Bioassay Analysis using R. J Stat Softw 2005;12: 
28. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural 
respiratory syncytial virus infection. J Med Virol 2006;78:1493–1497. 
29. Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ. Kinetics of the 
neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J 
Med Virol 2013;85:2020–2025. 
30. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng N-Y, Mays I, 
Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. Rapid cloning of 
high-affinity human monoclonal antibodies against influenza virus. Nature 2008;453:667–
671. 
31. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, McCausland M, 
Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng N-Y, Lee J-H, 
Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O’Donnell CD, Yewdell 
JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly 
cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 
influenza virus infection. J Exp Med 2011;208:181–193. 
32. Li G-M, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng N-Y, Lee J-H, Huang 
M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed 
Defective respiratory syncytial virus IgA memory  
 
 24 
R. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors 
broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 2012;109:9047–9052. 
33. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, 
Pulendran B, Wilson PC, Wittawatmongkol O, Yoksan S, Angkasekwinai N, 
Pattanapanyasat K, Chokephaibulkit K, Ahmed R. Rapid and Massive Virus-Specific 
Plasmablast Responses during Acute Dengue Virus Infection in Humans. J Virol 
2012;86:2911–2918. 
34. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and 
vaccine antigens. N Engl J Med 2007;357:1903–1915. 
35. Mills V J, Van Kirk JE, Wright PF, Chanock RM, Fishburne IE. Experimental Respiratory 
Syncytial Virus Infection of Adults: Possible Mechanisms of Resistance to Infection and 
Illness. J Immunol 1971;107:123–130. 
36. Watt PJ, Robinson BS, Pringle CR, Tyrrel DAJ. Determinants of susceptibility to challenge 
and the antibody response of adult volunteers given experimental respiratory syncytial virus 
vaccines. Vaccine 1990;8:231–236. 
37. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory 
syncytial virus infection in adults. J Infect Dis 2004;190:373–378. 
38. Lee FE-H, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans 
with A2 respiratory syncytial virus. Antiviral Res 2004;63:191–196. 
39. Fujimoto C, Takeda N, Matsunaga A, Sawada A, Tanaka T, Kimoto T, Shinahara W, 
Sawabuchi T, Yamaguchi M, Hayama M, Yanagawa H, Yano M, Kido H. Induction and 
maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG 
levels after influenza infection in adults. Influenza Other Respir Viruses 2012;6:396–403. 
Defective respiratory syncytial virus IgA memory  
 
 25 
40. Barclay WS, al-Nakib W, Higgins PG, Tyrrell DA. The time course of the humoral immune 
response to rhinovirus infection. Epidemiol Infect 1989;103:659–669. 
41. Lee FE-H, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibody-secreting cells 
during acute respiratory syncytial virus infection in adults. J Infect Dis 2010;202:1659–1666. 
42. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral Immunity Due to Long-Lived Plasma 
Cells. Immunity 1998;8:363–372. 
43. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu 
Rev Immunol 2005;23:367–386. 
44. Mora JR, von Andrian UH. Differentiation and homing of IgA-secreting cells. Mucosal 
Immunol 2008;1:96–109. 
45. Mora JR, Iwata M, Eksteen B, Song S-Y, Junt T, Senman B, Otipoby KL, Yokota A, 
Takeuchi H, Ricciardi-Castagnoli P, Rajewsky K, Adams DH, von Andrian UH. Generation 
of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314:1157–
1160. 
46. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, 
Villanacci V, Plebani A, Knowles DM, Rescigno M, Cerutti A. Intestinal bacteria trigger T 
cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion 
of the cytokine APRIL. Immunity 2007;26:812–826. 
47. Cerutti A, Chen K, Chorny A. Immunoglobulin Responses at the Mucosal Interface. Annu 
Rev Immunol 2011;29:273–293. 
48. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 
2007;25:5467–5484. 
49. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621–663. 
Defective respiratory syncytial virus IgA memory  
 
 26 
50. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in 
vivo. Immunity 2000;13:443–451. 
51. Borsutzky S, Cazac BB, Roes J, Guzmán CA. TGF-beta receptor signaling is critical for 
mucosal IgA responses. J Immunol Baltim Md 1950 2004;173:3305–3309. 
52. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, 
LaRocque RC, Wrammert J, Ryan ET, Qadri F, Calderwood SB, Harris JB. Antigen-specific 
memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 
2009;77:3850–3856. 
53. Clements ML, Murphy BR. Development and persistence of local and systemic antibody 
responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin 
Microbiol 1986;23:66–72. 
54. McNamara PS, Fonceca AM, Howarth D, Correia JB, Slupsky JR, Trinick RE, Al Turaiki 
W, Smyth RL, Flanagan BF. Respiratory syncytial virus infection of airway epithelial cells, 
in vivo and in vitro, supports pulmonary antibody responses by inducing expression of the B 
cell differentiation factor BAFF. Thorax 2013;68:76–81. 
55. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr 
Opin Virol 2013;3:468–474. 
56. Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. 
Curr Top Microbiol Immunol 2013;372:259–284. 
 
  
Defective respiratory syncytial virus IgA memory  
 
 27 
Figure Legends 
Fig. 1. RSV specific nasal IgA is a superior correlate of protection to serum neutralization 
titer. 
(A) Serum neutralizing antibody was determined by plaque reduction neutralization and nasal 
IgA by ELISA. Baseline serum neutralizing (top), nasal IgA against whole RSV (middle), and 
nasal anti-RSV fusion (F) protein (bottom) antibody levels in uninfected (○) vs. infected (●) 
subjects are shown. Serum neutralization includes 4 infant samples (∆) and 3 reference serum 
standards (■ Wyeth 06937, 06938, 06939. Horizontal bars indicate the median. (B) Logistic 
regression of probability of protection with baseline serum neutralizing (top), nasal whole RSV 
IgA (middle), and nasal RSV fusion (F) protein IgA (bottom) antibody levels with predicted 
probability (solid line) and point-wise 95% confidence band (shaded) are shown. OR = odds 
ratio (and 95% confidence interval), P-values for unpaired Mann-Whitney-Wilcoxon (U) test or 
two-tailed z-test as appropriate are shown (ns = P > 0.05, * = P < 0.05, ** = P < 0.01, *** = P < 
0.001).   
 
Fig. 2. Serum and nasal antibody increase following infection but are not maintained. 
Healthy adult volunteers were challenged intranasally with RSV A M37.  Serum and nasal 
lavage was taken at baseline and 28 days post-inoculation.  A subset of subjects returned for 
further blood and nasal sampling 6-12 months later (nominally day +180).  Serum neutralizing 
antibody was determined by plaque reduction neutralization and nasal IgA by ELISA.  (A) Fold-
change vs. baseline of serum in serum PRNT (top), nasal IgA against whole RSV (middle), and 
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nasal anti-RSV fusion (F) protein (bottom) antibody levels in uninfected (○) vs. infected (●) 
subjects. Horizontal bars indicate the median. (B) Individual plots showing trend in antibody 
levels at baseline, day +28, and +180.  P-values for unpaired Mann-Whitney-Wilcoxon (U) test 
are shown (ns = P > 0.05, * = P < 0.05, ** = P < 0.01, *** = P < 0.001). 
 
Fig 3. RSV induced plasmablast expansion correlates with IgG and IgA increment. 
(A) Antigen-specific antibody secreting cells (ASCs) were enumerated using B cell ELISpot 
with whole RSV lysate where sufficient PBMCs were available. Uninfected (PCR-) subjects (n = 
12) are shown in blue, infected (PCR+) subjects (n = 16) in red.  (B) Peak antigen-specific ASC 
frequencies as % of total Ig+ cells for infected subjects. Horizontal bars indicate the median. (C) 
Correlation of fold-change in serum neutralizing antibody with peak IgG+ ASC frequency.  (D) 
Correlation of fold-change in nasal IgA against RSV with peak IgA+ ASC frequency (data from 
27 subjects; nasal IgA in one subject could not be measured).  (E) Correlation of peak ASC 
frequency with pre-infection baseline serum neutralizing antibody titers.  ASC frequencies are 
expressed as log10 per million PBMC.  P values for unpaired Mann-Whitney-Wilcoxon (U) tests 
and or Spearman’s rank correlation coefficient (Rs) are shown as appropriate. (○) Uninfected 
subjects, (●) infected subjects. 
 
Fig 4. Antigen-specific IgG+ memory B cells are induced by RSV infection. 
PBMCs were obtained on days 0 and 28 post-inoculation and memory B cells (MBCs) 
polyclonally activated. Total and antigen-specific immunoglobulin-producing cells were then 
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enumerated using ELISpot. (A) Antigen-specific IgG+ MBC frequencies for uninfected (○) vs. 
infected (●) subjects at baseline and day 28 post-inoculation (infected only).  P > 0.05 for all 
comparisons except where shown. MBC frequencies are expressed as % of total Ig+ cells. 
Horizontal bars indicate the median. (B) Fold-change (log2) of IgG+ MBCs post-infection 
compared with baseline for infected subjects (n = 17). Horizontal bars indicate the median. (C) 
Correlation between peak acute ASC frequency at day 10 and fold-change over baseline (log2) of 
RSV specific IgG+ MBC.  Spearman’s rank correlation coefficient (Rs) or P-values for unpaired 
Mann-Whitney-Wilcoxon (U) test are shown as appropriate. RSV: whole RSV, MV: measles 
virus, FP: purified RSV fusion protein. 
 
Fig 5. RSV infection fails to induce IgA+ memory B cells. 
PBMCs were obtained on days 0 and 28 post-inoculation and memory B cells (MBCs) activated 
polyclonally in vitro. Total and antigen-specific immunoglobulin-producing cells were then 
enumerated using B-cell ELISpot as before. Data for infected subjects exhibiting adequate 
PBMC responses to in vitro stimulation only (n = 17) is shown. (A) Frequency of IgA+ MBCs at 
baseline (pre-infection) and (B) convalescence (day +28).  Subjects experimentally challenged 
with RSV A M37 were compared with patients naturally infected with pandemic influenza 
A/H1N1/09 (7 exhibited adequate response to stimulation and were analyzed). (C) IgG+ MBC 
frequencies and (D) IgA+ MBC frequencies at day 28 post-inoculation (RSV) and day 28-42 
post-hospitalization (H1N1) are shown. Horizontal bars indicate the median. P-values for 
unpaired Mann-Whitney-Wilcoxon (U) test are shown as appropriate. RSV: whole RSV, MV: 
measles virus, FP: purified RSV fusion protein. 
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 Uninfected (n = 
27) 
Infected (n = 
34) 
P 
Median (range) age (years) 23 (18-39) 21 (18-50) ns 
Gender (M:F) 17:10 18:16 ns 
Ethnicity 
White 
Black 
Asian 
Mixed 
Other 
 
21 
4 
0 
2 
0 
 
28 
1 
2 
1 
2 
 
ns 
ns 
ns 
ns 
ns 
Median (IQR) cumulative† 
symptom score 
9 (0.8 – 20.3) 26.5 (9.6 – 41.9) P = 0.004 
Median (IQR) cumulative† 
viral load (log10 copies / mL)  
0 4.0 (3.1 – 5.2) NA 
Table 1. Demographic, clinical and virological data from 61 individuals experimentally 
inoculated with RSV A Memphis 37. 
IQR = interquartile range.  † = trapezoidal area under the curve.  P-values for unpaired Mann-
Whitney-Wilcoxon (U) test or χ2 test for comparison of uninfected vs. infected are shown. 
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Supplementary methods 
Symptom scores and clinical cold 
Eight symptoms were evaluated in the symptom diary: nasal discharge, nasal congestion, 
sneezing, cough, sore throat, headache, feverishness and fatigue. Subjects were asked to score 
each symptom 0 (absent), 1 (mild), 2 (moderate), 3 (severe). A clinical cold was defined as 2 out 
of 3 of: a cumulative 14-day symptom score of ≥14; a subjective feeling of a cold; nasal 
discharge for ≥3 days. Symptoms were evaluated over a longer period than in Jackson’s original 
description to account for an anticipated slower onset and longer duration of illness with RSV 
compared with rhinovirus (E1). 
Viruses and viral antigens 
RSV A Memphis 37 (Meridian Lifesciences, Memphis, Tennessee, US) was used for challenge 
(E2, E3). Doses of 103 to 106 PFU had previously been equally effective at producing 
symptomatic infection in healthy adults. RSV antigen lysates were produced by three passages in 
HEp-2 cells followed by lysis in 1% Triton-X (Sigma). Uninfected cells were used to produce 
HEp-2 control antigen. Protein concentrations of the RSV and HEp-2 lysates were 7.7mg / mL 
and 12.0mg / mL respectively. RSV antigen titer was estimated by ELISA to be 1:16,000. UV-
inactivated influenza A/H1N1/England/195 was a gift from Wendy Barclay, Imperial College 
London. 
Purified RSV F protein was made from a cDNA clone encoding the RSV F ectodomain (residues 
26 to 513; Genbank accession number AAS93654.1) using human-preferred codons (GenScript 
USA Inc.), cloned into a pCD5 expression vector containing a triple Strep-tag II (IBA, 
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Germany). This was transfected into HEK293T cells (ATCC CRL-11268) as described. F protein 
was purified using Strep-tactin Sepharose beads (IBA, Germany). 
Sample collection 
Nasal washes were collected by instillation of 0.9% saline and washing the nose 10 times. 
Aliquots were snap frozen for later RNA extraction and remaining supernatants stored at −80°C. 
Peripheral blood mononuclear cells (PBMCs) were separated using Ficoll Paque PLUS (GE 
Healthcare) according to the manufacturer’s instructions and re-suspended in fetal calf serum 
(FCS)/10% dimethylsulphoxide for storage in liquid nitrogen. Serum was stored at −80°C. 
RSV detection 
RSV was detected in nasal lavage by real-time polymerase chain reaction (RT-PCR) for 
nucleoprotein (N) gene as previously described (E4) except that random hexamer primers 
(Qiagen) were used for cDNA synthesis. RSV N-gene copy number was estimated using a DNA 
plasmid standard curve. All subjects additionally had nasal lavage tested for a panel of 
respiratory viruses by multiplex PCR at day 0 and +7. 
Antibody assays 
Serum neutralizing antibody titer was determined by plaque reduction in HEp-2 cells.  Serum 
samples were heat-inactivated and triplicate 2-fold serum dilutions were made in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma). These were subsequently added to confluent HEp-2 
monolayers. Media alone was used as a non-neutralizing negative control and palivizumab 
(Synagis, Medimmune) as a positive neutralization control. Plates were incubated for 48 hours 
and monolayers fixed with methanol+2% H2O2. RSV was detected by immunoperoxidase 
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staining as described (E5). Plaques were counted using the AID iSpot Reader (Oxford 
Biosystems Cadama, UK) with manual verification. 
Nasal IgA titer was determined by enzyme-linked immunosorbent assay (ELISA). Ninety-six-
well plates (Nunc Maxisorb, Thermofisher Scientific) were coated with 5 µg/mL RSV antigen or 
0.1 µg/mL F protein. Two-fold dilutions of nasal lavage supernatant were made in PBS/1% 
bovine serum albumin (BSA). A serum sample with a previously determined titer of RSV IgA 
was used as a positive control. Diluted lavage supernatant was added to each well and incubated 
overnight at room temperature. Plates were developed using peroxidase-conjugated anti-human 
IgA (Sigma A0295) followed by tetramethylbenzidine (Sigma). Absorption at 450nm was 
measured on the SpectraMAX 384 PLUS device (Molecular Devices). Endpoint titers were 
calculated using the highest titer exhibiting an optical density of >2x the plate background. 
Observed endpoint titers were corrected for dilution using the ratio of serum to nasal lavage urea 
before analysis as described (E6), except urea was measured using the Urea Assay Kit (Abcam 
ab83362). 
Detection of antibody secreting cells by B cell ELISpot 
Antibody secreting cells (ASCs) were detected using enzyme-linked immunospot (ELISpot). 
Briefly, 96-well plates (MSHAN4B50 Millipore, UK) were coated anti-human IgG, IgA, IgM 
(Jackson Immunoresearch), RSV antigen, F protein, or UV-inactivated influenza virus. Fifty-
thousand PBMCs were added to duplicate wells, serial 3-fold dilutions were made in Roswell 
Park Memorial Institute (RPMI) medium/10% FCS and plates were incubated for 16 hours. For 
memory B cells, additional plates were coated with 10µg/mL measles antigen (Meridian 
Lifesciences), and 5µg/mL HEp-2 antigen, 2.5µg/mL keyhole limpet hemocyanin (KLH, Sigma), 
and media as negative controls. Duplicate serial 5-fold dilutions were made and cells were 
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incubated for 4 hours at 37°C. ASCs were detected using biotinylated anti-human IgG (Jackson 
Immunoresearch), IgA, or IgM (both Life Technologies), horseradish peroxidase-avidin D 
(Vector Labs) and 3-amino-9-ethylcarbazole (Sigma). Spots were counted on the AID iSpot 
Reader. Total ASCs were expressed as spot-forming cells / 106 PBMC and antigen-specific 
ASCs as % of total Ig-secreting cells. 
Polyclonal activation of memory B cells 
PBMCs were cultured in vitro according to the method of Crotty et al (E7). Briefly, PBMCs 
were incubated for 5 days with a mitogen mix containing, pokeweed mitogen extract (kindly 
donated by Rafi Ahmed, Emory Vaccine Center), CpG ODN 2006 (Qiagen) and S.aureus Cowan 
protein A (Sigma). The alternative polyclonal activation mix described by Tengvall et al. was 
used in a subset of samples (E8). ASCs were detected by B cell ELISpot as above. Subjects 
exhibiting a total Ig+ cell responses the below the 10th centile in either the day 0 or day 28 
sample for either IgG or IgA were excluded (n = 9) as inadequate responders to stimulation. 
Logistic regression model of protective effect of antibody 
Binary response variables (infected vs. uninfected) were related to continuous explanatory 
variables (log2 antibody titer) by a generalized linear model (GLM) using a binomial (logit) link 
function (logistic regression). Odds ratios (OR) and 95% confidence intervals (CI) of the OR for 
the explanatory variables were calculated. The GLM was used to predict the probability of 
protection (i.e. being uninfected) for a given antibody titer. A grid of 120 points of antibody titer 
across the range of theoretical values from lowest to highest observed titer was used to produce 
the prediction curves (solid lines of Fig. 1B). Point-wise 95% confidence intervals for the 
predicted response curves were derived by a bootstrap percentile method. Briefly, 5,000 
bootstrap replicates of the data were generated by random sampling with replacement, a GLM 
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was fitted to each replicate, and the predicted response values for the 120-point antibody titer 
grid derived, producing a 120 by 5,000 matrix of predicted response values. The 2.5th and 97.5th 
centiles for each row of the matrix were extracted yielding the lower and upper bound of the 
estimated 95% CI for the predicted response at that level of antibody titer (shaded region of Fig. 
1B). 
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Supplementary Tables 
Supplementary Table E1. Proportions of individuals achieving levels of nasal anti-RSV IgA 
post-infection associated with stratified probability of protection. 
 
  
Predicted probability of 
protection (%) 
% of subjects achieving at least this level at 
convalescence 
 Anti-RSV-IgA Anti-F-IgA 
100 0 0 
80 21 9 
60 56 41 
40 79 76 
20 100 97 
0 100 100 
Defective respiratory syncytial virus IgA memory  
 
 46 
Supplementary Figure Legends 
Supplementary Fig. E1. Study design and infection rate 
(A) Volunteers were inoculated with RSV A M37 and followed up with blood and nasal 
sampling up to day +180. (B) RSV was detected in nasal washes by quantitative PCR. Common-
cold symptoms were determined using symptom questionnaires. 
Supplementary Fig. E2. Virus-specific serum IgG and IgA do not correlate with protection 
from RSV infection. 
Serum and was taken at baseline (7-14 days pre-inoculation) and 28 days post-inoculation. 
Serum anti-RSV IgG and IgA and anti-fusion (F)-protein IgG and IgG antibodies were 
determined by ELISA. (A) Baseline serum IgG against whole RSV (left), and F-protein (right) 
antibody levels in uninfected (○) vs. infected (●) subjects. (B) Baseline serum IgA against whole 
RSV (left), and F-protein (right) antibody levels in uninfected (○) vs. infected (●) subjects. (C) 
Correlation of serum IgA and nasal IgA against whole RSV (left) and F-protein (right). P-values 
for unpaired Mann-Whitney-Wilcoxon (U) test or Spearman’s rank correlation coefficient (Rs) 
are shown (ns = P > 0.05). 
Supplementary Fig. E3. Acute plasmablasts measured by flow cytometry and correlation of 
RSV F-protein-specific response. 
(A) Flow cytometric analysis of plasmablasts in whole blood following RSV M37 infection.  
One representative subject is shown. Plots were gated on CD3-/CD20-/CD19int/+ lymphocytes 
and plasmablasts identified as CD27hi/CD38hi. Plasmablast frequencies are expressed as % of 
CD19int/+ lymphocytes. (B) Correlation of fold-change in serum neutralizing antibody with peak 
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F-protein-specific IgG+ ASC frequency.  (C) Correlation of fold-change in nasal IgA against F-
protein with peak IgA+ ASC frequency (data from 27 subjects; nasal IgA in one subject could not 
be measured).  (D) Correlation of peak F-protein-specific ASC frequency with pre-infection 
baseline serum neutralizing antibody titers.  ASC frequencies are expressed as log10 per million 
PBMC.  P values for unpaired Mann-Whitney-Wilcoxon (U) tests and or Spearman’s rank 
correlation coefficient (Rs) are shown as appropriate. (○) Uninfected subjects, (●) infected 
subjects.  FP: purified RSV fusion protein. 
 
Supplementary Fig. E4. Peak plasmablast frequencies following RSV infection are not 
associated with viral load or severity of symptoms. 
Antigen-specific ASCs were identified ex vivo by B cell ELISpot and frequencies are expressed 
as % total Ig+ cells. (A) Correlation of peak ASC frequency with cumulative daily viral load 
(trapezoidal area under curve).  (B) Correlation of peak ASC frequency with cumulative daily 
upper respiratory tract (URT) symptom score (trapezoidal area under curve). Spearman’s rank 
correlation coefficient (Rs) is shown.  All correlations non-significant. 
 
Supplementary Fig. E5. Pre-existing RSV specific memory B cells have no impact on 
symptoms, viral load or antibody titers. 
PBMCs from days 0 and 28 post-inoculation were polyclonally activated in vitro. Total and 
antigen-specific immunoglobulin-producing cells were revealed using B-cell ELISpot. MBC 
frequencies are expressed as % total Ig+ cells. Correlation between baseline antigen-specific IgG+ 
MBC frequencies and (A) cumulative symptoms scores, (B) cumulative daily viral load, (C) 
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serum neutralizing antibody, (D) nasal anti-RSV IgA, and (E) nasal anti-F IgA at baseline. 
Spearman’s rank correlation coefficient (Rs) is shown.  FP: purified RSV fusion protein. 
 
Supplementary Fig. E6 No difference is seen in RSV specific memory B cells when 
polyclonally stimulating with an alternative mitogen mix. 
PBMCs from 6 subjects demonstrating robust total and antigen-specific IgG+ MBC activation 
following the method of Crotty et al. (SAC + PWM) were selected for alternative in vitro 
stimulation using recombinant human BAFF, IL-15, and CpG ODN 2006.  Total (A) IgA+ and 
(B) IgG+ MBCs (day 0 and day 28 combined) following stimulation with both methods. (C) RSV 
specific IgA+ MBCs at day 0 and day 28 post-infection.  (D) RSV specific IgA MBC for day 0 
and day 28 combined comparing two MBC activation methods.  P-values for unpaired Mann-
Whitney-Wilcoxon (U) test are shown as appropriate (ns = P > 0.05, * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001).  CpG: CpG oligodeoxynucleotide 2006. rBAFF: recombinant human B cell 
activating factor. rIL-15: recombinant human interleukin 15. SAC: protein A from 
Staphylococcus aureus Cowan. PWM: pokeweed mitogen. Both MBC activation methods 
received CpG ODN 2006 at the same concentration. 
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Supplementary Figures 
Figure E1 
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Figure E2 
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Figure E4 
  
Defective respiratory syncytial virus IgA memory  
 
 53 
Figure E5 
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Figure E6 
